Research Note: Effect of Cardiomyopathy & Diabetes Mellitus on SDMA in Cats

Sign in to Print/View PDF

Considering the potential benefits of renoprotective nutritional treatment in cats in preazotemic stages of kidney disease, early diagnosis of kidney disease is critical. Symmetric dimethylarginine (SDMA) increases as glomerular filtration rates decrease, with a mean time of 17 months before serum creatinine elevations are observed. However, little is known about the influence of comorbidities on SDMA in cats. Human models have shown that SDMA may be influenced by other diseases. This study examined possible relationships between SDMA and hypertrophic cardiomyopathy and diabetes mellitus. In cats, SDMA does not appear to be affected by hypertrophic cardiomyopathy. However, diabetes mellitus appears to lower SDMA levels, making it a less predictable marker for cats with concomitant diabetes mellitus and chronic kidney disease.

Source

Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Practice Tools

Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)